Literature DB >> 19863175

De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy.

Jason Westin, Peter McLaughlin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19863175     DOI: 10.3109/10428190903324244

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  4 in total

Review 1.  Primary hepatosplenic CD5-positive diffuse large B-cell lymphoma: a case report with literature review.

Authors:  Xiaohui Zhang; Manhua Sun; Ling Zhang; Haipeng Shao
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

2.  Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens.

Authors:  Fangwen Zhang; Ling Li; Lei Zhang; Xin Li; Xiaorui Fu; Xinhua Wang; Jingjing Wu; Zhenchang Sun; Fei Kong; Liangliang Ren; Mingzhi Zhang
Journal:  Blood Lymphat Cancer       Date:  2019-08-19

3.  Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.

Authors:  Hee Young Na; Ji-Young Choe; Sun Ah Shin; Hyun-Jung Kim; Jae Ho Han; Hee Kyung Kim; So Hee Oh; Ji Eun Kim
Journal:  PLoS One       Date:  2019-10-23       Impact factor: 3.240

4.  Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.

Authors:  Zijun Y Xu-Monette; Meifeng Tu; Kausar J Jabbar; Xin Cao; Alexandar Tzankov; Carol Visco; Lalitha Nagarajan; Qingqing Cai; Santiago Montes-Moreno; Yuji An; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Xiaoying Zhao; Michael B Møller; John P Farnen; Jane N Winter; Miguel A Piris; Roberto N Miranda; L Jeffrey Medeiros; Ken H Young
Journal:  Oncotarget       Date:  2015-03-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.